6-08-2025, 18:00

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Notified -
Globe Newswire6-08-2025, 18:00
7-03-2023, 15:05

AB2 Bio Completes Enrolment in Pivotal Phase 3 Trial of

Topline pivotal Phase 3 results expected during second half of 2023Potential new treatment option in ultra-rare,
Globe Newswire7-03-2023, 15:05